Literature DB >> 23843194

Aortic valve stenosis and arterial hypertension: a synopsis in 2013.

Vasiliki Katsi1, Maria Marketou, Manolis S Kallistratos, Thomas Makris, Athanasios J Manolis, Dimitris Tousoulis, Christodoulos Stefanadis, Panos Vardas, Ioannis Kallikazaros.   

Abstract

Systemic hypertension and aortic valve stenosis (AVS) are both age-related diseases. The pathophysiology of AVS shares some similarities with essential hypertension, which might be the link between the two diseases. Although AS is usually related with low blood pressure levels, approximately one third of patients with severe AS suffer from arterial hypertension, a percentage that can increase up to 50 % according some studies. This review will summarize various aspects regarding the prevalence the pathophysiology and the natural history of those two diseases that seems to be linked, as well as the effect of blood pressure and antihypertensive treatment on various echocardiographic parameters in patients with AVS.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23843194     DOI: 10.1007/s11906-013-0357-0

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  54 in total

1.  Administration of angiotensin-converting enzyme inhibitors is associated with slow progression of mild aortic stenosis in Japanese patients.

Authors:  Kana Wakabayashi; Takeshi Tsujino; Yoshiro Naito; Akira Ezumi; Masaaki Lee-Kawabata; Shinji Nakao; Akiko Goda; Yasushi Sakata; Kazuhiro Yamamoto; Takashi Daimon; Tohru Masuyama
Journal:  Heart Vessels       Date:  2010-11-10       Impact factor: 2.037

2.  Systemic pressure does not directly affect pressure gradient and valve area estimates in aortic stenosis in vitro.

Authors:  Julia Mascherbauer; Christina Fuchs; Martin Stoiber; Heinrich Schima; Elisabeth Pernicka; Gerald Maurer; Helmut Baumgartner
Journal:  Eur Heart J       Date:  2008-05-22       Impact factor: 29.983

3.  The effect of aortic valve replacement on survival.

Authors:  F Schwarz; P Baumann; J Manthey; M Hoffmann; G Schuler; H C Mehmel; W Schmitz; W Kübler
Journal:  Circulation       Date:  1982-11       Impact factor: 29.690

4.  Hypertension in valvar aortic stenosis.

Authors:  H Ikram; D E Marshall; S M Moore; P J Bones
Journal:  N Z Med J       Date:  1979-03-28

5.  Effects of angiotensin converting enzyme inhibitors in hypertensive patients with aortic valve stenosis: a drug withdrawal study.

Authors:  J Jiménez-Candil; J Bermejo; R Yotti; C Cortina; M Moreno; J L Cantalapiedra; M A García-Fernández
Journal:  Heart       Date:  2005-10       Impact factor: 5.994

6.  Systolic hypertension in critical aortic stenosis and the effect of valve replacement.

Authors:  E Ie; W Mook; A P Shapiro
Journal:  J Hum Hypertens       Date:  1996-02       Impact factor: 3.012

7.  Ramipril retards development of aortic valve stenosis in a rabbit model: mechanistic considerations.

Authors:  Doan Tm Ngo; Irene Stafford; Aaron L Sverdlov; Weier Qi; Ronald D Wuttke; Yuan Zhang; Darren J Kelly; Helen Weedon; Malcolm D Smith; Jennifer A Kennedy; John D Horowitz
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

8.  Factors associated with calcific aortic valve degeneration in the elderly.

Authors:  M Lindroos; M Kupari; J Valvanne; T Strandberg; J Heikkilä; R Tilvis
Journal:  Eur Heart J       Date:  1994-07       Impact factor: 29.983

9.  Hemodynamic effects of the angiotensin-converting enzyme inhibitor, ramipril, in patients with mild to moderate aortic stenosis and preserved left ventricular function.

Authors:  Kevin D O'Brien; Xue-Qiao Zhao; David M Shavelle; Michael T Caulfield; Rebecca A Letterer; Samir R Kapadia; Jeffrey L Probstfield; Catherine M Otto
Journal:  J Investig Med       Date:  2004-04       Impact factor: 2.895

10.  ACE inhibition attenuates uremia-induced aortic valve thickening in a novel mouse model.

Authors:  Mikko A Simolin; Tanja X Pedersen; Susanne Bro; Mikko I Mäyränpää; Satu Helske; Lars B Nielsen; Petri T Kovanen
Journal:  BMC Cardiovasc Disord       Date:  2009-03-03       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.